![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1372565
ºÏ¹ÌÀÇ Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® : À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°North America Intravenous Immunoglobulin Market Size and Forecasts, Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Application, Distribution Channel, End User, and Country |
ºÏ¹ÌÀÇ Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 50¾ï 4,200¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2030³â¿¡´Â 87¾ï 4,700¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2022-2030³âÀÇ CAGRÀº 7.1%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ºÏ¹ÌÀÇ Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº ¸é¿ª±Û·ÎºÒ¸° »ç¿ëÀÇ Áõ°¡¿Í ¸é¿ªºÎÀü ÁúȯÀÇ À¯º´·ü »ó½ÂÀÔ´Ï´Ù.
Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀÇ ¼ºÀåÀ» ÇâÇÑ ½ÅÁ¦Ç° Ãâ½Ã¿Í ½ÂÀÎ ±âȸ
ÃÖ±Ù ¼ö³â°£ ºÏ¹Ì Á¤¸ÆÁÖ»ç ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå¿¡¼´Â ´Ù¾çÇÑ ½ÃÀå °³Ã´ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. 2023³â 4¿ù, ¿¬±¸°³¹ßÇü ¹ÙÀÌ¿ÀÀǾàǰÀÇ ¼±µÎÁÖÀÚÀÎ ´ÙÄÉ´ÙÁ¦¾àÀº ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ 2-16¼¼ ¼Ò¾Æ¿¡¼ ¿ø¹ß¼º ¸é¿ª°áÇÌÁõ(PI) Ä¡·áÁ¦·Î HYQVIAÀÇ »ç¿ëÀ» È®´ëÇϱâ À§ÇÑ Ãß°¡ »ý¹°ÇÐÀûÁ¦Á¦ Çã°¡ ½Åû(sBLA)À» ½ÂÀι޾ҽÀ´Ï´Ù. 2022³â, ij³ª´Ù º¸°ÇºÎ´Â ¸é¿ª°áÇÌÁõ¿¡ °É¸° ij³ª´ÙÀεéÀ» À§ÇÑ »õ·Î¿î ¸é¿ª±Û·ÎºÒ¸°(IG) Ä¡·áÁ¦ÀÎ HYQVIAÀÇ¿ù1ȸ Åõ¿©¸¦ ½ÂÀÎÇß½À´Ï´Ù. 2021³â 2¿ù, ÈÀÌÀÚÀÇ ¸¸¼º ¿°Áõ¼º Å»¼öÃʼº ´Ù¹ß¼º ½Å°æ¿°(CIDP) Ä¡·áÁ¦ PANZYGA(10% ¾×»ó ¸é¿ª±Û·ÎºÒ¸° Á¦Á¦)ÀÇ sBLA ½ÂÀΠȹµæ.
À¯Çüº° ÀλçÀÌÆ®
ºÏ¹Ì Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀº À¯Çüº°·Î IgG, IgA, IgM, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â IgG ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí 2022-2030³â »çÀÌ °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿ëµµº° ÀλçÀÌÆ®
ºÏ¹Ì Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀº ¿ëµµº°·Î ¸é¿ª°áÇÌÁõ, ¸¸¼º ¿°Áõ¼º Å»¼öÃʼº ´Ù¹ß¼º ½Å°æº´Áõ, Ư¹ß¼º Ç÷¼ÒÆÇ°¨¼Ò¼º Àڹݺ´, ´Ù¹ß¼º ¿îµ¿½Å°æº´Áõ, Àú°¨¸¶±Û·ÎºÒ¸°Ç÷Áõ, ±æ¶û-¹Ù·¹ ÁõÈıº, ƯÁ¤ Ç×ü°áÇÌÁõ, ¿°Áõ¼º ±Ùº´Áõ, ÁßÁõ ±Ù¹«·ÂÁõ, ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â±îÁö °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2022³â¿¡´Â ¸é¿ª°áÇÌÁõ ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç 2022-2030³â °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À¯Åë ä³Î¿¡ ±â¹ÝÇÑ ÀλçÀÌÆ®
À¯Åë ä³Î¿¡ µû¶ó ºÏ¹Ì Á¤¸Æ³» ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀº º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹ ¹× ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â¿¡´Â º´¿ø ¾à±¹ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2022-2030³â °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚ¿¡ ±â¹ÝÇÑ ÀλçÀÌÆ®
ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó ºÏ¹Ì Á¤¸Æ³» ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀº º´¿ø, Àü¹® Ŭ¸®´Ð ¹× ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â¿¡´Â º´¿ø ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí 2022-2030³â »çÀÌ °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÚ°¡¸é¿ªÁúȯ ȯÀÚ´Â ¸é¿ª±Û·ÎºÒ¸° Á¤¸ÆÁÖ»ç·Î Ä¡·áÇÕ´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯÀº ¸é¿ªÃ¼°è°¡ ÀÚ½ÅÀÇ Á¶Á÷°ú ¼¼Æ÷¸¦ À߸ø °ø°ÝÇÏ´Â ÁúȯÀÔ´Ï´Ù. °Ç°ÇÑ ¼¼Æ÷¿¡ ´ëÇÑ ÀÌ·¯ÇÑ ºñÁ¤»óÀûÀÎ ¸é¿ª ¹ÝÀÀÀ¸·Î ÀÎÇØ ¸¸¼º ¿°Áõ, Àå±â ¹× ½Ã½ºÅÛ ¼Õ»óÀÌ ¹ß»ýÇÕ´Ï´Ù. ÇÇ·Î, °üÀýÅë, ±ÙÀ° ¾àÈ, ÇǺΠ¹ßÁø, ½Å°æ Àå¾Ö µîÀº ÀÚ°¡ ¸é¿ª ÁúȯÀÇ ÀüÇüÀûÀΠ¡ÈÄ¿Í Áõ»ó Áß ÀϺÎÀÔ´Ï´Ù. ±æ¶û-¹Ù·¹ ÁõÈıº(GBS), ÁßÁõ ±Ù¹«·ÂÁõ(MS), ·ù¸¶Æ¼½º °üÀý¿°(RA), Àü½Å¼º È«¹Ý¼º ·çǪ½º(LE), ¸é¿ª¼º Ç÷¼ÒÆÇ °¨¼ÒÁõ(ITP)°ú °°Àº ÀÚ°¡¸é¿ª ÁúȯÀÇ Áõ»óÀº IVIG Ä¡·á¸¦ ÅëÇØ ¿Ï鵃 ¼ö ÀÖ½À´Ï´Ù. ÀÌ Ä¡·á¹ýÀÇ ÀåÁ¡Àº ºü¸¥ Áõ»ó ¿ÏÈ¿Í Àå±âÀûÀÎ È¿°ú Áö¼ÓÀ¸·Î ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù.
Intermountain Healthcare¿¡ µû¸£¸é ÀÚ°¡¸é¿ªÁúȯ ¹× ¸é¿ª ¸Å°³ ÁúȯÀº ¹Ì±¹ÀÎ 2,350¸¸ ¸í¿¡¼ 5,000¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é ·ù¸¶Æ¼½º°üÀý¿°(RA)Àº ÀÚ°¡¸é¿ª¼º °üÀý¿° Áß °¡Àå ÈçÇÑ ÁúȯÀ¸·Î, ¹Ì±¹ ¼ºÀÎ 4¸í Áß 1¸íÀÌ ¾Î°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ÁßÁõ±Ù¹«·ÂÁõ Àç´Ü¿¡ µû¸£¸é ÁßÁõ±Ù¹«·ÂÁõ(MG)ÀÇ À¯º´·üÀº ¹Ì±¹ Àα¸ 10¸¸ ¸í´ç 14-20¸íÀ¸·Î ÃßÁ¤µË´Ï´Ù. ij³ª´ÙÀÇ ÁßÁõ±Ù¹«·ÂÁõ À¯º´·üÀº 100¸¸ ¸í´ç 23¸í, À¯º´·üÀº 100¸¸ ¸í´ç 263¸íÀ¸·Î ÃßÁ¤µÇ¸ç, ÀÌ ¼öÄ¡´Â Áö³ ¼ö½Ê³â°£ ¾ÈÁ¤ÀûÀ¸·Î À¯ÁöµÇ°í ÀÖ½À´Ï´Ù.
¸é¿ª±Û·ÎºÒ¸° »ç¿ë Áõ°¡·Î ºÏ¹Ì Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå °È
Ç÷Àå À¯·¡ ¸é¿ª±Û·ÎºÒ¸°Àº ÀÚ°¡¸é¿ªÁúȯ, ¿°Áõ¼º Áúȯ µîÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ°ú ±Þ¼º ¿°Áõ¼º Áúȯ ¿Ü¿¡µµ ¿ø¹ß¼º ¸é¿ª°áÇÌÁõ(PIDD), ¸¸¼º ¿°Áõ¼º Å»¼öÃʼº ´Ù¹ß¼º ½Å°æ¿°(CIDP), ´Ù¹ß¼º ¿îµ¿½Å°æº´Áõ(MMN) µîÀÌ ¸é¿ª±Û·ÎºÒ¸°À¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ¸¸¼º ¹× ±Þ¼º ÁúȯÀÔ´Ï´Ù. ¸é¿ª±Û·ÎºÒ¸°Àº ¶ÇÇÑ °¨¿°, ÇǺÎÁúȯ, ·ù¸¶Æ¼½º ¹× ½ÅÀåÁúȯ, ½ÉÀåÁúȯÀÇ °ü¸®¿¡µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ Á¤¸Æ³» ¸é¿ª±Û·ÎºÒ¸°¿¡ ´ëÇÑ ¼ö¿ä´Â ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ ÀÌ·¯ÇÑ Ç×ü°¡ »ç¿ëµÊ¿¡ µû¶ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
Takeda Pharmaceutical Co Ltd, Grifols SA, Pfizer Inc., ADMA Biologics, Inc., Bio Products Laboratory Ltd., Octapharma AG, Kedrion SpA., CSL Ltd., LFB Group, Prothya Biosolutions B.V. µîÀº Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.
ºÏ¹ÌÀÇ Á¤¸ÆÁÖ»ç¿ë ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå¿¡ °üÇÑ º¸°í¼¸¦ ÀÛ¼ºÇÒ ¶§¿¡ ÂüÁ¶ÇÑ ÁÖ¿ä 1Â÷ Á¤º¸¿ø ¹× 2Â÷ Á¤º¸¿øÀ¸·Î´Â Myasthenia Gravis Foundation of America, Journal of Allergy and Clinical Immunology, Genetic and Rare Diseases Information Center, Immune Deficiency Foundation, GBS Foundation, Centers for Disease Control and Prevention µîÀÌ ÀÖ½À´Ï´Ù.
The North America intravenous immunoglobulin market size was valued at US$ 5.042 Bn in 2022 and is expected to reach US$ 8.747 Bn by 2030; it is estimated to record a CAGR of 7.1% from 2022 to 2030. The North America intravenous immunoglobulin market growth is primarily driven by increase in use of immunoglobulins and rising prevalence of immunodeficiency diseases
New Product Launches and Approvals Opportunity for Growth of Intravenous Immunoglobulin Market
In recent years, there have been various developments in the intravenous immunoglobulin market in North America. Market players have been launching new products and seeking regulatory approvals for their offerings. In April 2023, Takeda Pharmaceutical Company Limited, an R&D-driven biopharmaceutical leader, received a supplemental Biologics License Application (sBLA) approval from the US Food and Drug Administration (FDA) to expand the use of HYQVIA to treat primary immunodeficiencies (PI) in children belonging to the age group of 2-16 years. Only HYQVIA's subcutaneous immune globulin (ScIG) infusion allows for monthly administration. In 2022, Health Canada approved HyQvia, a new Immunoglobulin (IG) treatment for Canadians with immune deficiencies. In February 2021, Pfizer Inc. received an sBLA approval for PANZYGA (10% liquid intravenous immunoglobulin preparation) to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
Type-Based Insights
The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022-2030.
Application-Based Insights
Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022-2030.
Distribution Channel -Based Insights
Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022-2030.
End User - Based Insights
Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022-2030.
Patients with autoimmune diseases are treated with intravenous immunoglobulins. Autoimmune diseases are conditions wherein the immune system accidentally attacks its own tissues or cells. Chronic inflammation, and organ and system damage result from this aberrant immune reaction against healthy cells. Fatigue, joint pain, muscle weakness, skin rashes, and neurological disturbances are a few of the typical signs and symptoms of autoimmune diseases. Symptoms of autoimmune diseases such as Guillain-Barre syndrome (GBS), myasthenia gravis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (LE), and immune thrombocytopenia (ITP) can be alleviated with the IVIG therapy. Benefits of this therapy include the rapid relief of symptoms and long-lasting effects, leading to improved quality of life among patients.
According to the Intermountain Healthcare, autoimmune and immune-mediated diseases and conditions affect 23.5-50 million Americans. According to the Centers for Disease Control and Prevention, rheumatoid arthritis (RA) is the most prevalent type of autoimmune arthritis, and 1 in 4 adults in the US has arthritis. As per the Myasthenia Gravis Foundation of America, Inc., the prevalence of myasthenia gravis (MG) is estimated at 14-20 per 100,000 of the US population. In Canada, the incidence of MG is estimated to be 23 per 1 million person-years, with a prevalence of 263 per 1 million people, and the numbers have been stable over the past few decades.
Increase in Use of Immunoglobulins Bolsters North America Intravenous Immunoglobulins Market
Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is rising with the surging use of these antibodies for treating various conditions.
Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the leading companies operating in the intravenous immunoglobulin market.
A few of the major primary and secondary sources referred to while preparing the report on the North America intravenous immunoglobulin market are the Myasthenia Gravis Foundation of America, Journal of Allergy and Clinical Immunology, Genetic and Rare Diseases Information Center, Immune Deficiency Foundation, GBS Foundation, Centers for Disease Control and Prevention